An expert discusses proactive management strategies for atopic dermatitis (AD), emphasizing daily gentle skin care, proper use of topical treatments, avoidance of outdated therapies such as routine antihistamines or steroids, and a shift toward personalized, flare-preventive care using newer therapeutic options.
An expert discusses practical strategies for assessing atopic dermatitis severity, highlighting simple yet effective tools such as the Investigator Global Assessment (IGA) scale, palm-based body surface area (BSA) estimation, and the Pruritus Numerical Rating Scale (NRS) to guide personalized treatment and improve symptom tracking in routine clinical care.
An expert discusses the formal diagnostic criteria and diverse clinical presentations of atopic dermatitis, emphasizing patient-centered assessment, challenges in distinguishing it from similar conditions, and the critical role of education and skin care in effective management, particularly in primary care settings.
An expert discusses advancements in the management of atopic dermatitis, emphasizing early recognition, updated nonsteroidal treatments, accurate differential diagnosis, and the importance of collaboration between dermatology and primary care providers to improve patient outcomes.
A panelist emphasizes that shared decision-making in anaphylaxis management is essential, combining evidence-based guidelines with individual patient circumstances and preferences—especially regarding newer options like intranasal epinephrine—to ensure timely, confident use while addressing practical concerns, such as access, cost, and education.
A panelist highlights how neffy, a needle-free, portable intranasal epinephrine device, addresses key unmet needs by reducing needle anxiety, enabling easy use by nonmedical caregivers, offering longer shelf life and temperature stability, and improving timely administration to prevent severe anaphylaxis outcomes, as demonstrated in clinical case examples.
A panelist discusses that the intranasal epinephrine device causes only mild, expected adverse effects such as nasal discomfort and headache, avoids injection-related risks, demonstrates rapid symptom improvement in pediatric food challenge studies, and offers practical advantages such as higher heat tolerance for storage and a longer shelf life compared with traditional autoinjectors.
A panelist discusses a newly approved intranasal epinephrine device for treating anaphylaxis in both children and adults, highlighting its needle-free delivery using a nasal spray with an absorption enhancer that ensures effective, safe drug uptake comparable to injections—even under nasal congestion—offering a promising alternative to traditional epinephrine autoinjectors.
A panelist discusses how intranasal epinephrine represents a significant advance over traditional autoinjectors by eliminating needles, addressing user anxiety and real-world barriers, and potentially improving adherence and timely treatment in anaphylaxis emergencies.
A panelist discusses how barriers such as cost, fear of injections, and lack of confidence delay epinephrine use in anaphylaxis and explains how intranasal delivery and updated guidelines may reduce hesitation and improve timely, effective treatment through better education and accessibility.
A panelist discusses the critical importance of early epinephrine administration in anaphylaxis for preventing severe outcomes, explaining its multireceptor action and lifesaving potential, while highlighting how intranasal delivery could enhance timely use and empower caregivers with faster, more accessible treatment options.
A panelist discusses how intranasal epinephrine could transform anaphylaxis management by improving accessibility, reducing treatment delays, and addressing underuse of epinephrine—especially in pediatric and high-risk populations—while emphasizing the need for better education and more user-friendly interventions to improve outcomes.
Panelists discuss billing and coding procedures for skin scanning devices, focusing on the use of unlisted Current Procedural Terminology (CPT) 99 codes with proper documentation and modifiers, the importance of clear communication with billing teams, available educational resources to aid primary care settings, and operational considerations including scope-of-practice variations for device use among clinical staff.
Panelists discuss an interactive case session emphasizing the nuanced evaluation of suspicious skin lesions, highlighting tools such as the DermaSensor for risk scoring, the ugly duckling concept, and the importance of combining clinical judgment with technology to guide biopsy decisions and patient follow-up across diverse skin types.
Panelists discuss that decisions to forgo biopsy often weigh patient risk and lesion characteristics with noninvasive tools offering valuable reassurance; while familiarity with artificial intelligence (AI) aids varies, these technologies—used judiciously and alongside clinical expertise—can boost diagnostic confidence, though limitations and integration challenges remain.
Panelists discuss that successful adoption of artificial intelligence (AI) skin cancer detection tools requires proven effectiveness, easy integration into clinical workflows, appropriate reimbursement, and use as supportive aids that complement—not replace—clinical judgment.
Panelists discuss how visual examination remains the primary method for evaluating suspicious skin lesions in everyday practice, emphasizing clinical judgment, patient-reported changes, and the growing—but still limited—role of artificial intelligence (AI) tools, while underscoring the importance of vigilance, especially in high-risk and underserved populations with limited access to dermatology.
Panelists discuss the challenges of skin cancer evaluations, highlighting patient fears, systemic access barriers, and provider concerns about overreferral, while emphasizing the importance of clear communication, responsible resource use, and cautious adoption of emerging tools such as artificial intelligence (AI), with clinical judgment and trusted educational resources remaining central to care.
Panelists discuss the anxieties primary care providers face in skin cancer evaluation—particularly the fear of missing a malignancy—while highlighting challenges such as limited diagnostic confidence, delayed dermatology access, and disparities in underserved areas, emphasizing the need for better tools and support to empower frontline clinicians and improve early detection.
Panelists discuss the vital role of primary care providers in early skin cancer detection, highlighting the need for improved diagnostic confidence, integration of artificial intelligence (AI) tools, and efficient workflows to overcome time and resource constraints, ultimately aiming to reduce delays and improve patient outcomes.
A panelist discusses how shared decision-making between healthcare providers and patients should guide epinephrine device selection, with two real-world case studies demonstrating successful Neffy use in treating anaphylaxis with rapid symptom resolution.
A panelist discusses how Neffy addresses unmet needs through superior temperature stability (tolerating up to 122°F for 3-4 days), extended shelf life (24-30 months), and needle-free administration that eliminates injection-related complications.
A panelist discusses how real-world studies in Japan showed Neffy successfully treated grade 2 anaphylaxis symptoms in pediatric patients with a median resolution time of 16 minutes and minimal adverse effects.
A panelist discusses how FDA bracketing studies demonstrated that Neffy's pharmacokinetics and pharmacodynamics fall within the established safety and efficacy range of existing epinephrine auto-injectors, with rapid onset within one minute.
A panelist discusses how Neffy represents a novel intranasal epinephrine delivery system using three FDA-approved components: epinephrine, Intravail absorption enhancer, and a proven nasal spray device already used in other medications.
A panelist discusses how multiple barriers prevent timely epinephrine use, including patient reluctance to use auto-injectors, lack of device availability, uncertainty about administration timing, and cost concerns, leading to widespread underuse.
A panelist discusses how early epinephrine administration significantly reduces severe complications, prevents progression to life-threatening stages, and decreases the need for additional medical interventions like hospitalization or multiple doses.
A panelist discusses how epinephrine is the first and only evidence-based first-line treatment for anaphylaxis, working through alpha and beta adrenergic receptors to rapidly reverse life-threatening symptoms unlike slower-acting antihistamines.
A panelist discusses how anaphylaxis affects approximately 40 million people in the United States with severe systemic reactions involving multiple organ systems, leading to over 500,000 emergency room visits annually.
Panelist discusses how patient cases demonstrate the importance of considering nonsteroidal agents in patients of color (due to hypopigmentation risks) and elderly patients (due to skin thinning), concluding that effective atopic dermatitis management requires proper moisturizing, appropriate corticosteroid cycling, and proactive twice-weekly maintenance with newer nonsteroidal topicals to prevent long-term complications.
